Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan 'Unusual Suspect' But Pipeline 'Hunger' A Perfect Match For Heptares

This article was originally published in Scrip

Executive Summary

With Scrip still reeling from the news earlier this week that Pfizer and Allergan have called off their $160bn mega-merger, news broke that former darling of the UK biotech scene Heptares, now a wholly-owned subsidiary and the 'R&D engine' of Japanese company Sosei Group Corp., has secured a notable licensing deal with Allergan. Scrip caught up with Heptares CEO Malcolm Weir to get his take on the fall of PfizerGan (PfAllergan?), and of course the small matter of securing a partnership deal worth up to $3.34bn plus potential royalties.

Advertisement

Related Content

Sosei CEO Says Recent $199m Equity Raising Will Help Pipeline Expansion
Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration
CNS Licensing Trends: Volume Falls, Values Rise
Heptares' GPCR Discovery Pact With PeptiDream Focused On Inflammation
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Allergan's Fishing For Deals, But Don't Expect A Big Catch
Heptares-Powered Sosei's Incoming CEO Explains What Happens Next

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC032210

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel